Professor Biao He from the University of Georgia discusses ongoing efforts to develop intranasal COVID-19 vaccines through his companies, CyanVac and Blue Lake Biotechnology. Unlike injectable vaccines, intranasal vaccines aim to provide immunity directly in the respiratory tract, where the virus enters.
Early trials have shown promising results, with no fever reported among participants and an 86% protection rate against symptomatic infection for three months. While further trials are underway, the vaccine could be available in about two years. Professor He emphasized the importance of continuing vaccination efforts to combat COVID-19 effectively.
